Qiagen Stock Price, News & Analysis

Tracer Biotechnologies and QIAGEN (NYSE: QGEN) have announced a strategic partnership to develop and commercialize minimal residual disease (MRD) testing solutions for solid tumors using QIAGEN's QIAcuity digital PCR platform. The collaboration aims to create sensitive, cost-effective, and decentralized blood-based MRD tests to monitor cancer recurrence and guide treatment decisions. Tracer offers two MRD solutions: Tracer dPCR for tumor-informed testing and Tracer WGS, an AI-powered whole-genome ctDNA platform for tumor-agnostic detection. This partnership strengthens QIAGEN's position in oncology and expands their companion diagnostic capabilities, while advancing Tracer's mission to democratize MRD testing across institutions.

QIAGEN (NYSE: QGEN) has announced two strategic partnerships to expand its minimal residual disease (MRD) testing capabilities in oncology. The company partnered with Tracer Biotechnologies to develop blood-based MRD tests for solid tumors using QIAcuity digital PCR systems, and with Foresight Diagnostics to create a kit version of its CLARITY™ NGS assay for lymphoma. These partnerships aim to advance decentralized, non-invasive tools for cancer monitoring and personalized treatment decisions. The collaborations will support pharmaceutical companies' clinical trials and companion diagnostic development. QIAGEN's comprehensive MRD portfolio includes sample technologies, testing platforms, and digital insights solutions, with plans to launch an upgraded QIAsymphony Connect version in late 2025.

Foresight Diagnostics and QIAGEN (NYSE: QGEN) have announced a strategic worldwide partnership to develop and commercialize a kit version of Foresight's CLARITY™ assay for minimal residual disease (MRD) detection in lymphoma and other blood cancers. The collaboration combines Foresight's MRD detection technology with QIAGEN's global molecular diagnostic expertise. The partnership aims to create a standardized, regulated diagnostic kit that would be unique in offering both central laboratory service and diagnostic capabilities for ctDNA-based MRD testing. This kit, once validated and approved, will support clinical decision-making and therapeutic strategies for hematological cancer patients, enabling personalized treatment approaches through next-generation sequencing technology.

QIAGEN (NYSE: QGEN) has announced a commercial partnership with ID Solutions, a French provider of digital PCR assays, to expand its oncology research portfolio. The collaboration combines QIAGEN's global reach and automation expertise with ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will manufacture dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in cell-free DNA from plasma and genomic DNA from FFPE tissue.

The partnership will initially focus on European commercialization, with potential for expansion. This strategic move enhances QIAGEN's existing portfolio, which includes PanCancer Kits and over 200 LNA Mutation Assays available through its GeneGlobe platform. The collaboration aims to provide researchers with ready-to-use assays that deliver results in less than a day, supporting faster adoption of dPCR in oncology research.

QIAGEN (NYSE: QGEN) has announced the acquisition of Genoox for $70 million in cash, with potential additional milestone payments of up to $10 million. The acquisition brings Franklin, Genoox's AI-powered cloud platform for clinical decision support in genetic diseases, into QIAGEN's Digital Insights portfolio.

Franklin is currently used by over 4,000 healthcare organizations across 50+ countries and has processed more than 750,000 case interpretations. The platform helps analyze next-generation sequencing (NGS) data and provides real-time, AI-driven insights for clinical decision-making in genetic disorders, cancer treatments, and family planning.

The acquisition is expected to generate approximately $5 million in sales for 2025 with a neutral impact on adjusted EPS. QIAGEN plans to integrate its genomic content, including HGMD, COSMIC, and QKB databases, into the Franklin platform to enhance its interpretive capabilities.

QIAGEN (NYSE: QGEN) has announced upcoming leadership changes in its Supervisory Board. Stephen H. Rusckowski, current Chair of the Nomination & Governance Committee, will succeed Lawrence A. Rosen as Chairman following the Annual General Meeting on June 26, 2025. Rosen, who has served since 2013 and as Chairman since 2020, will step down after the meeting.

Additionally, Prof. Dr. Elaine Mardis, who has served since 2014, will not seek re-election. All other current Supervisory Board members will stand for re-election to one-year terms. Following these changes, the Supervisory Board will be streamlined to eight members, aligning with a plan announced in 2024.

Rusckowski, who joined the board in 2023, brings significant healthcare industry experience as former Chairman, President and CEO of Quest Diagnostics and former CEO of Philips Healthcare.

QIAGEN reported strong Q1 2025 results with net sales of $483 million, representing a 5% growth at actual rates and 7% growth at constant exchange rates (CER). The company achieved an adjusted diluted EPS of $0.55, exceeding their outlook. The adjusted operating income margin improved to 29.8%, up 4.1 percentage points from Q1 2024. Key growth pillars QIAstat-Dx and QuantiFERON posted double-digit sales gains. QIAGEN reaffirmed its FY 2025 outlook for about 4% CER sales growth and upgraded adjusted EPS outlook to about $2.35 CER. The company plans to expand its capital allocation strategy by introducing a dividend and seeking approval for a new $500 million share repurchase program. Additionally, Stephen H. Rusckowski is proposed to become the new Chairman of the Supervisory Board.

QIAGEN (NYSE: QGEN) has announced plans to initiate its first-ever annual cash dividend program, subject to shareholder approval at the Annual General Meeting on June 26, 2025. The initial proposed dividend is $0.25 per ordinary share, amounting to a total payout of approximately $54 million.

The record date is planned for July 2, 2025, with payment scheduled for July 10, 2025. The amended dividend policy aims to balance shareholder returns with maintaining flexibility for growth investments, considering factors such as distributable profits, R&D investments, working capital needs, and potential M&A opportunities.

QIAGEN has expanded its digital PCR portfolio with new solutions for lentivirus-based cell and gene therapies. The company introduced key products including the QIAcuity RCL Quant Kit for safety testing, new CGT dPCR assays for viral measurements, and a specialized Lentivirus Lysis Kit for improved workflow.

The expansion specifically targets quality control in the manufacturing of advanced treatments like CAR-T cell therapy, a personalized cancer immunotherapy. The new offerings provide:

• Enhanced detection of replication-competent lentivirus
• Eight different wet-lab verified lentiviral targets
• Improved accuracy in viral titer measurement
• Streamlined protocols for vector copy number determination

This portfolio enhancement strengthens QIAGEN's position as a quality control partner for biotech companies, CDMOs, and therapy developers. The solutions complement existing products for residual DNA quantification, mycoplasma testing, and viral vector analysis, supporting the growing cell and gene therapy industry's regulatory compliance needs.